Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential

被引:5
作者
Gleeson, Ferga C. [1 ]
Kipp, Benjamin R. [2 ]
Voss, Jesse S. [2 ]
Campion, Michael B. [2 ]
Minot, Douglas M. [2 ]
Tu, Zheng J. [3 ]
Klee, Eric W. [3 ]
Graham, Rondell P. [2 ]
Lazaridis, Konstantinos N. [1 ,4 ]
Henry, Michael R. [2 ]
Levy, Michael J. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Anat Pathol, Rochester, MN 55905 USA
[3] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN 55905 USA
[4] Mayo Clin, Ctr Individualized Med, Rochester, MN 55905 USA
关键词
FINE-NEEDLE-ASPIRATION; NEOADJUVANT CHEMORADIATION THERAPY; KRAS; MUTATIONS; CHEMORADIOTHERAPY; HETEROGENEITY; PREDICT; PIK3CA; GENE; RESISTANCE;
D O I
10.1016/j.gie.2015.01.050
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Targeted next-generation sequencing has the potential to stratify a tumor by molecular subtype and aid the development of a biomarker profile for prognostic risk stratification and theranostic potential. Objective: To assess the frequency and distribution of pathogenic alterations in malignant lymph node cytology specimens. Design: Multigene molecular profiling of archived malignant EUS-FNA lymph node cytology specimens using the Ion Ampliseq Cancer Hotspot Panel v2, which targets at least 2855 possible mutations within 50 cancer-associated genes. Setting: Single tertiary referral center. Patients: Sporadic, treatment naive, locally advanced primary rectal cancer by EUS-FNA (n = 76) who subsequently completed neoadjuvant therapy with on-site oncologic surgery. Main Outcome Measurements: The frequency and distribution of pathogenic alterations in malignant lymph node cytology specimens by the mitogen-activated protein kinase (MAPK) or phosphoinositide 3-kinase (PI3K) signaling pathways, by KRAS or NRAS wild-type lymph node status, by extramesenteric lymph node status, and by a complete pathologic response status. Results: Eleven patients (14.5%) were 50-gene panel wild-type. Sixty-five patients had 139 pathogenic alterations (2 [1-3] per patient) in 13 of 50 evaluated genes. The following represent a spectrum of identified alterations: TP53 (n = 52; 68.4%), APC (n = 36; 47.4%), KRAS (n = 22; 28.9%), FBXW7 (n = 8; 10.5%), NRAS (n = 6; 7.9%), PIK3CA (n = 4; 5.3%), SMAD4 (n = 3; 3.9%), and BRAF (n = 3; 3.9%). Pathogenic alterations were identified in the MAPK and PI3K signaling pathways in 41% and 5% of patients, respectively. Limitations: Findings were limited to a 50 cancer-associated gene analysis. Conclusions: Molecular EUS lymph node assessments using cancer "hotspot" panels can identify pathogenic alteration frequency and distribution and have theranostic potential for individualized patient care.
引用
收藏
页码:550 / +
页数:8
相关论文
共 31 条
[1]   Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration [J].
Al-Haddad, M ;
Wallace, MB .
CYTOPATHOLOGY, 2006, 17 (01) :3-9
[2]   FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm [J].
Aydin, Iraz T. ;
Melamed, Rachel D. ;
Adams, Sarah J. ;
Castillo-Martin, Mireia ;
Demir, Ahu ;
Bryk, Diana ;
Brunner, Georg ;
Cordon-Cardo, Carlos ;
Osman, Iman ;
Rabadan, Raul ;
Celebi, Julide Tok .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (06)
[3]   Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases [J].
Baldus, Stephan E. ;
Schaefer, Karl-L. ;
Engers, Rainer ;
Hartleb, Dinah ;
Stoecklein, Nikolas H. ;
Gabbert, Helmut E. .
CLINICAL CANCER RESEARCH, 2010, 16 (03) :790-799
[4]   Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples [J].
Bournet, B. ;
Pointreau, A. ;
Souque, A. ;
Oumouhou, N. ;
Muscari, F. ;
Lepage, B. ;
Senesse, P. ;
Barthet, M. ;
Lesavre, N. ;
Hammel, P. ;
Levy, P. ;
Ruszniewski, P. ;
Cordelier, P. ;
Buscail, L. .
PANCREATOLOGY, 2012, 12 (01) :27-34
[5]   A MicroRNA-Based Test Improves Endoscopic Ultrasound-Guided Cytologic Diagnosis of Pancreatic Cancer [J].
Brand, Randall E. ;
Adai, Alex T. ;
Centeno, Barbara A. ;
Lee, Linda S. ;
Rateb, George ;
Vignesh, Shivakumar ;
Menard, Charles ;
Wiechowska-Kozlowska, Anna ;
Boldys, Hubert ;
Hartleb, Marek ;
Sanders, Michael K. ;
Munding, Johanna B. ;
Tannapfel, Andrea ;
Hahn, Stephan A. ;
Stefanczyk, Ludomir ;
Tsongalis, Gregory J. ;
Whitcomb, David C. ;
Conwell, Darwin L. ;
Morisset, Jean A. ;
Gardner, Timothy B. ;
Gordon, Stuart R. ;
Suriawinata, Arief A. ;
Lloyd, Maura B. ;
Wylie, Dennis ;
Labourier, Emmanuel ;
Andruss, Bernard F. ;
Szafranska-Schwarzbach, Anna E. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (10) :1717-1723
[6]   Mucin Expression Pattern in Pancreatic Diseases: Findings From EUS-Guided Fine-Needle Aspiration Biopsies [J].
Carrara, Silvia ;
Cangi, Maria Giulia ;
Arcidiacono, Paolo Giorgio ;
Perri, Francesco ;
Petrone, Maria Chiara ;
Mezzi, Gianni ;
Boemo, Cinzia ;
Talarico, Anna ;
Dal Cin, Elena ;
Grassini, Greta ;
Doglioni, Claudio ;
Testoni, Pier Alberto .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (07) :1359-1363
[7]   KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis [J].
Clancy, Cillian ;
Burke, John P. ;
Coffey, J. Calvin .
SURGICAL ONCOLOGY-OXFORD, 2013, 22 (02) :105-111
[8]   Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab [J].
De Roock, Wendy ;
Jonker, Derek J. ;
Di Nicolantonio, Federica ;
Sartore-Bianchi, Andrea ;
Tu, Dongsheng ;
Siena, Salvatore ;
Lamba, Simona ;
Arena, Sabrina ;
Frattini, Milo ;
Piessevaux, Hubert ;
Van Cutsem, Eric ;
O'Callaghan, Chris J. ;
Khambata-Ford, Shirin ;
Zalcberg, John R. ;
Simes, John ;
Karapetis, Christos S. ;
Bardelli, Alberto ;
Tejpar, Sabine .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (16) :1812-1820
[9]   Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma [J].
Duldulao, Marjun P. ;
Lee, Wendy ;
Nelson, Rebecca A. ;
Li, Wenyan ;
Chen, Zhenbin ;
Kim, Joseph ;
Garcia-Aguilar, Julio .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (07) :2166-2171
[10]   The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma [J].
Edden, Y. ;
Wexner, S. D. ;
Berho, M. .
COLORECTAL DISEASE, 2012, 14 (05) :555-561